top of page
Search

A Milestone Worth Celebrating: Positive Results from the Panorama Study

Writer: Neuro-Behavioral Clinical Research
Neuro-Behavioral Clinical Research
2 hours ago
2 min read

At Neuro-Behavioral Clinical Research, we're honored to have played a part in something meaningful for the future of anxiety treatment. Definium Therapeutics has just announced positive results from the Panorama study, a Phase 3 clinical trial evaluating a new investigational treatment for Generalized Anxiety Disorder (GAD), commonly known simply as anxiety.


This is the third consecutive positive Phase 3 result for this treatment, following earlier successful studies in both anxiety and depression. For a condition that affects an estimated 26 million adults in the U.S., and one that hasn't seen a truly new treatment approach in nearly two decades, these results are significant.


What the Study Found


Participants who received the investigational treatment saw a statistically significant improvement in their anxiety symptoms, as measured by a standard clinical rating scale, compared to those who received a placebo. Improvements were seen quickly, within the first couple of days, and were sustained throughout the 12-week study period. The treatment was also generally well tolerated by participants.


These are topline results, meaning they represent the initial, high-level findings. The full data will undergo further review, and Definium plans to move toward a regulatory submission in the months ahead. It's important to note that this treatment remains investigational and is not yet approved by the FDA.


The People Behind the Progress


Numbers on a page don't capture what this study really represents: real people who showed up, session after session, because they believed in something bigger than their own diagnosis.


To every participant who trusted our site with their time, their story, and their courage, thank you. You are, in every sense of the word, “Medical Heroes”. Progress in mental health research doesn't happen in a lab alone; it happens because people like you are willing to be part of the answer.


And to our site team of coordinators, clinicians, and support staff who managed every visit, every check-in, and every detail with care and precision, this milestone belongs to you too. Your hard work behind the scenes is what makes studies like this possible.


Why This Matters


Anxiety disorders are common, but treatment options haven't evolved much in recent years. Many people cycle through multiple medications before finding one that works, often dealing with daily dosing and side effects along the way. Research like the Panorama study is aimed at exploring whether new approaches can offer meaningful relief with a different treatment experience.


We're proud to have contributed to that research, and even prouder of the community that made it possible.


Want to learn more about ongoing clinical trials at NBCR, or find out if you might qualify to participate in future research? Reach out to our team to learn more.


bottom of page